12/3
11:14 am
ions
Ionis Pharmaceuticals (NASDAQ:IONS) had its "buy" rating reaffirmed by analysts at Cowen Inc.
Low
Report
Ionis Pharmaceuticals (NASDAQ:IONS) had its "buy" rating reaffirmed by analysts at Cowen Inc.
12/2
07:00 am
ions
Ionis receives U.S. FDA Breakthrough Therapy designation for zilganersen for Alexander disease (AxD)
Low
Report
Ionis receives U.S. FDA Breakthrough Therapy designation for zilganersen for Alexander disease (AxD)
12/1
11:37 am
ions
Ionis Pharmaceuticals (IONS): Valuation Insights Following FDA Breakthrough Therapy Status for Olezarsen [Yahoo! Finance]
Low
Report
Ionis Pharmaceuticals (IONS): Valuation Insights Following FDA Breakthrough Therapy Status for Olezarsen [Yahoo! Finance]
12/1
09:22 am
ions
Ionis Pharmaceuticals (IONS) Up 5.4% After EMA Nod and $700M Raise—Has the Bull Case Changed? [Yahoo! Finance]
Low
Report
Ionis Pharmaceuticals (IONS) Up 5.4% After EMA Nod and $700M Raise—Has the Bull Case Changed? [Yahoo! Finance]
12/1
07:00 am
ions
Ionis receives U.S. FDA Breakthrough Therapy designation for olezarsen for severe hypertriglyceridemia (sHTG)
Low
Report
Ionis receives U.S. FDA Breakthrough Therapy designation for olezarsen for severe hypertriglyceridemia (sHTG)
11/18
09:24 am
ions
Akari Therapeutics Appoints Biotech Finance Leader, Kameel D. Farag as Interim Chief Financial Officer [Yahoo! Finance]
Low
Report
Akari Therapeutics Appoints Biotech Finance Leader, Kameel D. Farag as Interim Chief Financial Officer [Yahoo! Finance]
11/17
06:35 am
ions
Biogen acquires Alcyone to boost CNS drug delivery [Yahoo! Finance]
Low
Report
Biogen acquires Alcyone to boost CNS drug delivery [Yahoo! Finance]
11/15
06:41 am
ions
What Recent Clinical Trial Updates Mean for Ionis Pharmaceuticals Stock Valuation in 2025 [Yahoo! Finance]
Low
Report
What Recent Clinical Trial Updates Mean for Ionis Pharmaceuticals Stock Valuation in 2025 [Yahoo! Finance]
11/14
07:00 am
ions
DAWNZERA™ (donidalorsen) receives positive opinion from CHMP, recommended for approval in EU for hereditary angioedema (HAE)
Medium
Report
DAWNZERA™ (donidalorsen) receives positive opinion from CHMP, recommended for approval in EU for hereditary angioedema (HAE)
11/13
10:38 am
ions
Metagenomi culls 25% of its workforce and replaces CEO in reshuffle [Yahoo! Finance]
Low
Report
Metagenomi culls 25% of its workforce and replaces CEO in reshuffle [Yahoo! Finance]
11/13
01:06 am
ions
Ionis Prices Convertible Notes Offering to Refinance 2026 Convertible Notes [Yahoo! Finance]
Medium
Report
Ionis Prices Convertible Notes Offering to Refinance 2026 Convertible Notes [Yahoo! Finance]
11/13
12:39 am
ions
Ionis Prices Convertible Notes Offering to Refinance 2026 Convertible Notes
Medium
Report
Ionis Prices Convertible Notes Offering to Refinance 2026 Convertible Notes
11/12
04:00 pm
ions
Ionis to present at upcoming investor conferences
Medium
Report
Ionis to present at upcoming investor conferences
11/11
08:26 pm
ions
Tweedy, Browne Mutual Funds Q3 2025 Commentary [Seeking Alpha]
Low
Report
Tweedy, Browne Mutual Funds Q3 2025 Commentary [Seeking Alpha]
11/11
04:05 pm
ions
Ionis Announces Proposed Convertible Offering to Refinance 2026 Convertible Notes
Medium
Report
Ionis Announces Proposed Convertible Offering to Refinance 2026 Convertible Notes
11/10
08:03 am
ions
Ionis Pharmaceuticals (NASDAQ:IONS) had its price target raised by analysts at HC Wainwright from $100.00 to $110.00. They now have a "buy" rating on the stock.
Medium
Report
Ionis Pharmaceuticals (NASDAQ:IONS) had its price target raised by analysts at HC Wainwright from $100.00 to $110.00. They now have a "buy" rating on the stock.
11/8
09:40 am
ions
Groundbreaking pivotal study results of olezarsen for severe hypertriglyceridemia (sHTG) presented as a late breaker at AHA Scientific Sessions
Medium
Report
Groundbreaking pivotal study results of olezarsen for severe hypertriglyceridemia (sHTG) presented as a late breaker at AHA Scientific Sessions
11/6
08:00 am
ions
Ionis presents new data demonstrating long-term disease control with DAWNZERA™ (donidalorsen) at ACAAI 2025 Annual Meeting
Low
Report
Ionis presents new data demonstrating long-term disease control with DAWNZERA™ (donidalorsen) at ACAAI 2025 Annual Meeting
11/4
11:54 am
ions
Ionis Pharmaceuticals (NASDAQ:IONS) had its price target raised by analysts at Piper Sandler from $70.00 to $77.00. They now have an "overweight" rating on the stock.
Low
Report
Ionis Pharmaceuticals (NASDAQ:IONS) had its price target raised by analysts at Piper Sandler from $70.00 to $77.00. They now have an "overweight" rating on the stock.
11/1
08:05 pm
ions
US$81.91 - That's What Analysts Think Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) Is Worth After These Results [Yahoo! Finance]
Low
Report
US$81.91 - That's What Analysts Think Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) Is Worth After These Results [Yahoo! Finance]
10/30
04:14 pm
ions
Ionis Pharmaceuticals (NASDAQ:IONS) had its price target raised by analysts at TD Cowen from $59.00 to $99.00. They now have a "buy" rating on the stock.
Low
Report
Ionis Pharmaceuticals (NASDAQ:IONS) had its price target raised by analysts at TD Cowen from $59.00 to $99.00. They now have a "buy" rating on the stock.
10/30
12:03 pm
ions
Ionis Pharmaceuticals (NASDAQ:IONS) was given a new $99.00 price target on by analysts at Cowen Inc.
Low
Report
Ionis Pharmaceuticals (NASDAQ:IONS) was given a new $99.00 price target on by analysts at Cowen Inc.
10/30
12:03 pm
ions
Ionis Pharmaceuticals (NASDAQ:IONS) was given a new $94.00 price target on by analysts at Morgan Stanley.
Low
Report
Ionis Pharmaceuticals (NASDAQ:IONS) was given a new $94.00 price target on by analysts at Morgan Stanley.
10/30
11:28 am
ions
Ionis Pharmaceuticals (NASDAQ:IONS) had its price target raised by analysts at Royal Bank Of Canada from $80.00 to $82.00. They now have an "outperform" rating on the stock.
Low
Report
Ionis Pharmaceuticals (NASDAQ:IONS) had its price target raised by analysts at Royal Bank Of Canada from $80.00 to $82.00. They now have an "outperform" rating on the stock.
10/30
11:02 am
ions
Ionis Pharmaceuticals (NASDAQ:IONS) had its "strong-buy" rating reaffirmed by analysts at Raymond James Financial, Inc.. They now have a $89.00 price target on the stock, up previously from $85.00.
Low
Report
Ionis Pharmaceuticals (NASDAQ:IONS) had its "strong-buy" rating reaffirmed by analysts at Raymond James Financial, Inc.. They now have a $89.00 price target on the stock, up previously from $85.00.